Dr. Dasaradhi Lakkaraju
About Dr. Dasaradhi Lakkaraju
Dr. Dasaradhi Lakkaraju Chief Science Officer
Dr. Dasaradhi Lakkaraju serves as the Chief Science Officer. With over two decades of extensive expertise in analytical chemistry, Dr. Lakkaraju has made significant contributions to the pharmaceutical industry. His experience spans various formulations including solid orals, parenteral, and ophthalmic products. Dr. Lakkaraju's role involves spearheading intellectual property development projects, which include strategic use of reverse engineering techniques for Paragraph-IV filings.
Dr. Dasaradhi Lakkaraju Education and Expertise
Dr. Lakkaraju earned his Ph.D. from Osmania University. He furthered his expertise by completing postdoctoral fellowships in the Department of Chemistry at the University of Durham, England, New Mexico State University, and the Department of Pharmacology at the State University of New York, Stony Brook. His educational background has provided a strong foundation for his extensive work in analytical chemistry across the pharmaceutical sector.
Dr. Dasaradhi Lakkaraju Background in Analytical Chemistry
With 24 years of experience in analytical chemistry, Dr. Lakkaraju has specialized in various pharmaceutical formulations. His work in solid orals includes extended release and immediate release tablets, capsule formulations, and controlled substances. In the parenteral category, his expertise covers lyophilized products, liquids, oil-based depot formulations, suspensions, peptides, steroids, and oncology products. Additionally, he has significant experience in ophthalmic products, specifically liquids and suspensions.
Dr. Dasaradhi Lakkaraju Achievements
Dr. Lakkaraju has published 24 papers in peer-reviewed journals, contributing valuable knowledge to the field of pharmaceutical sciences. He holds patents in formulation development and has played a critical role in the development and approval of several Abbreviated New Drug Applications (ANDAs), New Drug Applications (NDAs), and 505(b)(2) submissions. His work has been integral to the reverse engineering techniques that support intellectual property development and Paragraph-IV filings, demonstrating his innovation and leadership in the industry.